✦ LIBER ✦

A tetravalent anti-CD3-CD19 bispecific monoclonal antibody (mAb) has antitumour activity,

Book ID: 120867723
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012590-00012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficiency of T cell triggering by anti-

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation

✍ Nathalie Jacobs; Alessandra Mazzoni; Delia Mezzanzanica; Donatella R. M. Negri; 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 421 KB

In vitro and in vivo antitumour activity

In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody

✍ Geoffrey A. Pietersz; Li Wenjun; Vivien R. Sutton; Jane Burgess; Ian F. C. McKen 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 831 KB

Bispecific Antibody-directed Antitumor A

Bispecific Antibody-directed Antitumor Activity of Human CD4+Helper/Killer T Cells Induced by Anti-CD3 Monoclonal Antibody plus Interleukin 2

✍ Nishimura, Takashi ;Nakamura, Yoshihiko ;Takeuchi, Yasuhiro ;Gao, Xiuhua ;Tokuda 📂 Article 📅 1991 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 225 KB

T-cell activation and B-cell depletion i

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

✍ Bernd Schlereth; Cornelia Quadt; Torsten Dreier; Peter Kufer; Grit Lorenczewski; 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 412 KB

T cell activation by a bispecific anti-C

T cell activation by a bispecific anti-CD3/anti-major histocompatibility complex class I antibody

✍ Eddy Roosnek; Alan Tunnacliffe; Antonio Lanzavecchia 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB

A tumor vaccine containing anti-CD3 and

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

✍ Claudia Haas; Maria Lulei; Philippe Fournier; Annette Arnold; Volker Schirrmache 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 636 KB

## Abstract We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell